02:22 PM EST - Avai Bio Inc : Announced together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank of genetically modified cells that overexpress the a-Klotho protein. The MCB now will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA. Avai Bio Inc
shares O.AVAI are trading off $0.06 at $0.24.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=6370873235297615
